Free Trial

Theratechnologies (THTX) Competitors

Theratechnologies logo
$1.21
-0.04 (-3.20%)
(As of 10/31/2024 ET)

THTX vs. TRVI, MGNX, ATYR, PYXS, INBX, RZLT, SOPH, XBIT, ZNTL, and DRUG

Should you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Trevi Therapeutics (TRVI), MacroGenics (MGNX), Atyr PHARMA (ATYR), Pyxis Oncology (PYXS), Inhibrx (INBX), Rezolute (RZLT), SOPHiA GENETICS (SOPH), XBiotech (XBIT), Zentalis Pharmaceuticals (ZNTL), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.

Theratechnologies vs.

Theratechnologies (NASDAQ:THTX) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Theratechnologies and Theratechnologies both had 3 articles in the media. Theratechnologies' average media sentiment score of 0.69 beat Trevi Therapeutics' score of 0.63 indicating that Theratechnologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Theratechnologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Trevi Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Trevi Therapeutics received 58 more outperform votes than Theratechnologies when rated by MarketBeat users. Likewise, 63.50% of users gave Trevi Therapeutics an outperform vote while only 52.73% of users gave Theratechnologies an outperform vote.

CompanyUnderperformOutperform
TheratechnologiesOutperform Votes
29
52.73%
Underperform Votes
26
47.27%
Trevi TherapeuticsOutperform Votes
87
63.50%
Underperform Votes
50
36.50%

Theratechnologies has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theratechnologies$84.32M0.66-$23.96M-$0.19-6.37
Trevi TherapeuticsN/AN/A-$29.07M-$0.39-7.55

Trevi Therapeutics has a net margin of 0.00% compared to Theratechnologies' net margin of -3.75%. Theratechnologies' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Theratechnologies-3.75% N/A -4.31%
Trevi Therapeutics N/A -49.92%-45.93%

Theratechnologies has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.

95.8% of Trevi Therapeutics shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Trevi Therapeutics has a consensus price target of $7.43, suggesting a potential upside of 152.67%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Theratechnologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Theratechnologies
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Trevi Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.22

Summary

Trevi Therapeutics beats Theratechnologies on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

THTX vs. The Competition

MetricTheratechnologiesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$55.64M$7.12B$5.36B$8.41B
Dividend YieldN/A8.77%5.22%4.20%
P/E Ratio-12.1016.06131.9317.57
Price / Sales0.66258.281,440.1578.36
Price / CashN/A50.1639.0633.56
Price / Book-2.695.674.744.57
Net Income-$23.96M$151.16M$115.43M$225.42M
7 Day Performance-3.20%-1.80%-0.86%-0.61%
1 Month Performance-1.63%5.92%3.61%1.50%
1 Year Performance34.44%39.97%38.90%32.94%

Theratechnologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
THTX
Theratechnologies
N/A$1.21
-3.2%
N/A+35.9%$55.64M$84.32M-12.10140
TRVI
Trevi Therapeutics
3.7366 of 5 stars
$3.11
-3.1%
$7.43
+138.9%
+67.2%$225.76MN/A-7.9720
MGNX
MacroGenics
3.8749 of 5 stars
$3.60
-8.6%
$8.11
+125.3%
-34.1%$225.48M$39.46M-1.64430Upcoming Earnings
News Coverage
ATYR
Atyr PHARMA
3.6874 of 5 stars
$3.24
-1.2%
$19.25
+494.1%
N/A$223.60M$588,000.00-3.5656Analyst Forecast
Short Interest ↓
Positive News
PYXS
Pyxis Oncology
1.3269 of 5 stars
$3.75
+3.9%
$9.00
+140.0%
+140.1%$222.83MN/A-3.0260Upcoming Earnings
INBX
Inhibrx
4.0772 of 5 stars
$15.37
-2.5%
$27.00
+75.7%
+12.0%$222.50M$1.69M0.00166
RZLT
Rezolute
3.8233 of 5 stars
$5.54
+3.4%
$11.57
+108.9%
+413.2%$222.35MN/A-4.1740Positive News
SOPH
SOPHiA GENETICS
2.3257 of 5 stars
$3.38
+2.7%
$6.50
+92.3%
-12.5%$220.98M$62.37M-3.31520Upcoming Earnings
XBIT
XBiotech
0.8047 of 5 stars
$7.24
+1.4%
N/A+84.8%$220.52M$4.01M-6.24100News Coverage
ZNTL
Zentalis Pharmaceuticals
1.9093 of 5 stars
$3.10
-6.6%
$10.78
+247.7%
-83.1%$220.44MN/A-1.14160Upcoming Earnings
DRUG
Bright Minds Biosciences
1.2085 of 5 stars
$49.50
+5.3%
N/A+3,436.6%$219.48MN/A-72.79N/AGap Up

Related Companies and Tools


This page (NASDAQ:THTX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners